Carl-Johan Zetterberg Boudrie

CFO since 2022 and interim CEO since 2025

Born 1978

Education

MSc in electrical engineering from the Royal Institute of Technology and MSc in economics from Stockholm University.

Other current assignments

Owner of Calan Consulting AB.


Principal work experience

CEO at Careium AB, CEO and CFO at DORO AB, CFO at Lekolar, Vice President Business Development at Beijer Electronics, and consultant at Capgemini Invent.

Shareholding in the company

5,142 ordinary shares.
Allotted 160,000 employee stock options under LTI 2024.

Magnus Kjellberg

CEO of Nextmune since 2017

Born 1973

Education

MSc in Business and Economics from the Stockholm School of Economics.

Other current assignments

Chairman and member of the board in a number of subsidiaries within the Group including Nextmune Holding BV, Nextmune BV, Nextmune US LLC, Nextmune AS, Nextmune Scandinavia AB, Nextmune Spain S.L., Nextmune Italy S.r.l., Vetruus Limited and Bova UK Limited.


Principal work experience

VP Corporate Strategy and M&A at Meda.

Shareholding in the company

3,426,047  ordinary shares.
Allotted 150,000 employee stock options under LTI 2024.

Alireza Tajbakhsh

CEO of VetFamily since 2022 and interim Head of MedTech since 2025

Born 1983

Education

MSc in Economics and Business Administration from the Stockholm School of Economics.

Other current assignments

Chairman of the board and board member of a number of subsidiaries within the Group. Board member of Famano AB, Precis Holding AB (Precis Digital), Seenthis AB, Proxer Midco AB and Stiftelsen Vin & Sprithistoriska museet.


Principal work experience

Group CEO of Omnicom Media Group Sweden, COO MTGx and Head of Digital MTG

Chairman of the Board OMD Sweden, Chairman of the Board PHD Sweden, Chairman of the Board Hearts & Science Sweden, Chairman of the Board Drum Sweden. Member of Board Splay Networks & Member of Board Godsmak.se.

Shareholding in the company

299,638 ordinary shares and 125,170 C shares.
Subscribed for a total of 10,000 warrants in the Company under LTI 2023.
Allotted 135,000 employee stock options under LTI 2024.

Stefano Santarelli

CEO of Indical Bioscience since 2021

Born 1981

Education

MSc in Economics and Business Administration (Honours) at LUISS Guido Carli University in Rome.

Other current assignments

Board member of Telenostic Limited, Board member of a number of subsidiaries within the Group.


Principal work experience

Ontario Teachers’ Pension Plan (OTPP), Bain & Company, TIM Telecom Italia, P&G.

Shareholding in the company

4,500 ordinary shares. 
Subscribed for a total of 81,905 warrants and 4,095 employee stock options under LTI 2023. 
Allotted 100,000 employee stock options under LTI 2024.

Martin Bengtson

Head of M&A since 2021

Born 1981

Education

MSc in Finance from the Stockholm School of Economics.

Other current assignments

Board member of HRR Holding AB and Danzinger Gatt Invest AB.


Principal work experience

Head of M&A at Doktor.se, Group M&A Manager at AniCura and Investment Manager at Nordic Capital.

Shareholding in the company

282,802 ordinary shares.
0 warrants.
Allotted 60,000 employee stock options under LTI 2024.

Maria Dahllöf Tullberg

Head of IR, Communications & Sustainability since 2021

Born 1981

Education

MSc in Accounting and Financial Management from the Stockholm School of Economics.

Principal work experience

Group Communications Director at AniCura, Head of Marketing & Communications at Moderna Försäkringar and Consultant at JKL Group.


Shareholding in the company

8,342 ordinary shares.
Subscribed for a total of 80,000 warrants under LTI 2023.
Allotted 143,612 employee stock options under LTI 2024.

Carl-Johan Ehn

General Counsel since 2022

Born 1974

Education

Master of laws - LLM from Lund University
Bachelor of Business Administration – Finance from Lund University

Other current assignments

Board member of Elding Oscarson Arkitekter AB
Board member of Tapster AB


Principal work experience

Vice President and Chief Counsel International Operations at Zoetis
Assistant General Counsel at Pfizer
Attorney (Advokat) at Mannheimer Swartling Law Firm

Shareholding in the company

19,660 ordinary shares.
Subscribed for a total of 50,000 warrants in the Company under LTI 2023.
Allotted 70,000 employee stock options under LTI 2024.

Bart Bremer

Chief People Officer since 2023

Born 1985

Education

MSc Economic Geography from University of Groningen

Bachelor of Business Administration Management, Economics & Law from Hanze University of Applied Sciences, Groningen

Principal work experience

Deputy CEO at Edward Lynx management consulting


Shareholding in the company

Allotted 70 000 personaloptioner under LTI 2024.